Pixantrone regulatory update

FDA's Oncologic Drugs Advisory Committee voted 9-0 against recommending approval of an NDA from Cell Therapeutics for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL)...